- Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Roche Annual General Meeting 2024
- Assemblée générale 2024 de Roche
More ▼
Key statistics
As of last trade Roche Holding AG (0TDF:LSE) traded at 31.27, 6.83% above its 52-week low of 29.27, set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 28.10 |
Offer | -- |
Previous close | 31.27 |
Average volume | 910.60 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 15.45 |
Market cap | 200.50bn USD |
EPS (TTM) | 1.97 USD |
Annual div (ADY) | 1.35 USD |
---|---|
Annual div yield (ADY) | 4.38% |
Div ex-date | Mar 14 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of May 15 2024 14:49 BST.
More ▼